Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

Review Article

Treatment of systolic hypertension: spotlight on recent studies with angiotensin II antagonists

Journal of Human Hypertension volume 19, pages 93–102 (2005)Cite this article

Abstract

Systolic blood pressure has a continuous, graded, strong, independent, and aetiologically significant relationship to mortality from coronary heart disease, stroke, and all cardiovascular diseases, as well as to all-cause mortality and life expectancy. Angiotensin II (AII) may be intimately involved in the pathogenesis of systolic hypertension through multiple mechanisms, including decreasing the elastin content and increasing the collagen content of the arterial wall, thickening and fibrotic remodelling of the vascular intima, and proliferating smooth muscle cells in the arterial wall, resulting in increased thickness, stiffening, and partial loss of contractility. AII antagonists may therefore offer hitherto unrecognized benefits (independent of blood pressure) on age-related vascular damage and provide particular benefits in patients with systolic hypertension. Recent evidence has demonstrated that losartan offers cardiovascular outcomes benefits in isolated systolic hypertension (ISH) associated with an excellent tolerability profile. This, in patients with ISH, AII antagonists more facilitate systolic BP control, providing cardiovascular protection and offering an excellent risk-benefit profile.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Neaton JD, Wentworth D . Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316 099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 1992; 152: 56–64.

    Article  CAS  Google Scholar 

  2. McInnes GT . Systolic hypertension as a cardiovascular risk factor. Blood Press 2002; 11: 134–143.

    Article  CAS  Google Scholar 

  3. Black HR . The paradigm has shifted, to systolic blood pressure. Hypertension 1999; 34: 386–387.

    Article  CAS  Google Scholar 

  4. Deedwania PC . The changing face of hypertension: is systolic blood pressure the final answer? Arch Intern Med 2002; 162: 506–508.

    Article  Google Scholar 

  5. Izzo Jr JL, Levy D, Black HR . Clinical Advisory Statement. Importance of systolic blood pressure in older Americans. Hypertension 2000; 35: 1021–1024.

    Article  Google Scholar 

  6. He J, Whelton PK . Elevated systolic blood pressure and risk of cardiovascular and renal disease: overview of evidence from observational epidemiologic studies and randomized controlled trials. Am Heart J 1999; 138: 211–219.

    Article  CAS  Google Scholar 

  7. Klag MJ et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996; 334: 13–18.

    Article  CAS  Google Scholar 

  8. Klahr S et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 1994; 330: 877–884.

    Article  CAS  Google Scholar 

  9. Chobanian AV et al. The Seventh Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003; 289: 2560–2572.

    Article  CAS  Google Scholar 

  10. Ramsay L et al. Guidelines for management of hypertension: report of the third working party of the British Hypertension Society. J Hum Hypertens 1999; 13: 569–592.

    Article  CAS  Google Scholar 

  11. European Society of Hypertension—European Society of Cardiology Guidelines Committee 2003. European Society of Hypertension—European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011–1053.

  12. McInnes GT . Angiotensin II antagonists in systolic blood pressure control. Hosp Med 2001; 62: 773–777.

    Article  CAS  Google Scholar 

  13. Tonkin A, Wing L . Management of isolated systolic hypertension. Drugs 1996; 51: 738–749.

    Article  CAS  Google Scholar 

  14. National High Blood Pressure Education Program Working Group Report on Hypertension in the Elderly. National High Blood Pressure Education Program Working Group. Hypertension 1994; 23: 275–285.

  15. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). (SHEP Cooperative Research Group). JAMA 1991; 265: 3255–3264.

  16. Staessen JA et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997; 350: 757–764.

    Article  CAS  Google Scholar 

  17. Liu L et al. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group. J Hypertens 1998; 16: 1823–1829.

    Article  CAS  Google Scholar 

  18. Mancia G, Seravalle G, Grassi G . Systolic blood pressure: an underestimated cardiovascular risk factor. J Hypertens 2002; 20 (Suppl 5): S21–S27.

    CAS  Google Scholar 

  19. Izzo Jr JL . Systolic hypertension, arterial stiffness, and vascular damage: role of the renin–angiotensin system. Blood Press Monit 2000; 5 (Suppl 2): S7–S11.

    Article  Google Scholar 

  20. Franklin SS et al. Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation 1997; 96: 308–315.

    Article  CAS  Google Scholar 

  21. Franklin SS et al. Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III. Hypertension 2001; 37: 869–874.

    Article  CAS  Google Scholar 

  22. Swales JD . Current status of hypertensive disease treatment: results from the evaluation and interventions for systolic blood pressure elevation: regional and global (EISBERG) project. J Hypertens Suppl 1999; 17: S15–S19.

    Article  CAS  Google Scholar 

  23. O'Rourke M . Arterial stiffness, systolic blood pressure, and logical treatment of arterial hypertension. Hypertension 1990; 15: 339–347.

    Article  CAS  Google Scholar 

  24. Izzo Jr JL, Shykoff BE . Arterial stiffness: clinical relevance, measurement, and treatment. Rev Cardiovasc Med 2001; 2: 29–40.

    PubMed  Google Scholar 

  25. Nawrot T, Den Hond E, Thijs L, Staessen JA . Isolated systolic hypertension and the risk of vascular disease. Curr Hypertens Rep 2003; 5: 372–379.

    Article  Google Scholar 

  26. Kannel WB . Elevated systolic blood pressure as a cardiovascular risk factor. Am J Cardiol 2000; 85: 251–255.

    Article  CAS  Google Scholar 

  27. Gubner RS . Major new developments affecting treatment and prognosis in hypertension. Trans Assoc Life Insur Med Dir Am 1990; 73: 97–114.

    CAS  PubMed  Google Scholar 

  28. Gubner RS . Systolic hypertension: a pathogenetic entity. Significance and therapeutic considerations. Am J Cardiol 1962; 9: 773–776.

    Article  CAS  Google Scholar 

  29. Kannel WB, Schwartz MJ, McNamara PM . Blood pressure and risk of coronary heart disease: the Framingham study. Dis Chest 1969; 56: 43–52.

    Article  CAS  Google Scholar 

  30. Kannel WB et al. Systolic blood pressure, arterial rigidity, and risk of stroke. The Framingham study. JAMA 1981; 245: 1225–1229.

    Article  CAS  Google Scholar 

  31. Miall WE . Systolic or diastolic hypertension—which matters most? Clin Exp Hypertens A 1982; 4: 1121–1131.

    CAS  PubMed  Google Scholar 

  32. Incidence and prediction of coronary heart disease in two Italian rural population samples followed-up for 20 years. Acta Cardiol 1982; 37: 129–145.

  33. Yano K, McGee D, Reed DM . The impact of elevated blood pressure upon 10-year mortality among Japanese men in Hawaii: the Honolulu Heart Program. J Chronic Dis 1983; 36: 569–579.

    Article  CAS  Google Scholar 

  34. Lichtenstein MJ, Shipley MJ, Rose G . Systolic and diastolic blood pressures as predictors of coronary heart disease mortality in the Whitehall study. Br Med J (Clin Res Ed) 1985; 291: 243–245.

    Article  CAS  Google Scholar 

  35. Rosenman RH, Sholtz RI, Brand RJ . A study of comparative blood pressure measures in predicting risk of coronary heart disease. Circulation 1976; 54: 51–58.

    Article  CAS  Google Scholar 

  36. Tverdal A . Systolic and diastolic blood pressures as predictors of coronary heart disease in middle aged Norwegian men. Br Med J (Clin Res Ed) 1987; 294: 671–673.

    Article  CAS  Google Scholar 

  37. Prognostic factors in the treatment of mild hypertension. The Management Committee of the Australian National Blood Pressure Study. Circulation 1984; 69: 668–676.

  38. Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and Follow-up Program Cooperative Group. JAMA 1979; 242: 2562–2571.

  39. Amery A et al. Efficacy of antihypertensive drug treatment according to age, sex, blood pressure, and previous cardiovascular disease in patients over the age of 60. Lancet 1986; 2: 589–592.

    Article  CAS  Google Scholar 

  40. MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party. Br Med J (Clin Res Ed) 1985; 291: 97–104.

  41. Pastor-Barriuso R et al. Systolic blood pressure, diastolic blood pressure, and pulse pressure: an evaluation of their joint effect on mortality. Ann Intern Med 2003; 139: 731–739.

    Article  Google Scholar 

  42. Stamler J, Stamler R, Neaton JD . Blood pressure, systolic and diastolic, and cardiovascular risks. US population data. Arch Intern Med. 1993; 153: 598–615.

    Article  CAS  Google Scholar 

  43. Lewington S et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903–1913.

    Article  Google Scholar 

  44. Williams B et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 2004; 328: 634–640.

    Article  Google Scholar 

  45. Whitworth JA, WHO, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21: 1983–1992.

    Article  Google Scholar 

  46. Swales JD . Current clinical practice in hypertension: the EISBERG (Evaluation and Interventions for Systolic Blood pressure Elevation-Regional and Global) project. Am Heart J 1999; 138: 231–237.

    Article  CAS  Google Scholar 

  47. Mancia G et al. Systolic vs diastolic blood pressure control in the hypertensive patients of the PAMELA population. Pressioni Arteriose Monitorate E Loro Associazioni. Arch Intern Med 2002; 162: 582–586.

    Article  Google Scholar 

  48. Mancia G, Grassi G . Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens 2002; 20: 1461–1464.

    Article  CAS  Google Scholar 

  49. Neaton JD et al. Treatment of mild hypertension study. Final results. Treatment of Mild Hypertension Study Research Group. JAMA 1993; 270: 713–724.

    Article  CAS  Google Scholar 

  50. Cushman WC, Brady WE, Gazdick LP, Zeldin RK . The effect of a losartan-based treatment regimen on isolated systolic hypertension. J Clin Hypertens (Greenwich) 2002; 4: 101–107.

    Article  CAS  Google Scholar 

  51. Farsang C et al. The efficacy and tolerability of losartan versus atenolol in patients with isolated systolic hypertension. Losartan ISH Investigators Group. J Hypertens 2000; 18: 795–801.

    Article  CAS  Google Scholar 

  52. Volpe M et al. Comparison of the blood pressure-lowering effects and tolerability of Losartan- and Amlodipine-based regimens in patients with isolated systolic hypertension. Clin Ther 2003; 25: 1469–1489.

    Article  CAS  Google Scholar 

  53. Hedner T . Management of hypertension: the advent of a new angiotensin II receptor antagonist. J Hypertens Suppl 1999; 17: S21–S25.

    Article  CAS  Google Scholar 

  54. Sega R . Efficacy and safety of eprosartan in severe hypertension. Eprosartan Multinational Study Group. Blood Press 1999; 8: 114–121.

    Article  CAS  Google Scholar 

  55. Ruilope L, Jager B, Prichard B . Eprosartan versus enalapril in elderly patients with hypertension: a double-blind, randomized trial. Blood Press 2001; 10: 223–229.

    Article  CAS  Google Scholar 

  56. Neutel JM, Bedigian MP . Efficacy of valsartan in patients aged>or=65 years with systolic hypertension. Clin Ther 2000; 22: 961–969.

    Article  CAS  Google Scholar 

  57. Malacco E et al. A randomized, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: The Val-Syst study. Clin Ther 2003; 25: 2765–2780.

    Article  CAS  Google Scholar 

  58. Wing LM, Arnolda LF, Upton J, Molloy D . Candesartan and hydrochlorothiazide in isolated systolic hypertension. Blood Press 2003; 12: 246–254.

    Article  Google Scholar 

  59. Neutel JM et al. The effects of candesartan cilexetil in isolated systolic hypertension: a clinical experience trial. J Clin Hypertens (Greenwich) 2000; 2: 181–186.

    CAS  Google Scholar 

  60. Weir MR et al. Efficacy of candesartan cilexetil as add-on therapy in hypertensive patients uncontrolled on background therapy: a clinical experience trial. ACTION Study Investigators. Am J Hypertens 2001; 14: 567–572.

    Article  CAS  Google Scholar 

  61. McClellan KJ, Markham A . Telmisartan. Drugs 1998; 56: 1039–1044.

    Article  CAS  Google Scholar 

  62. Sharpe M, Jarvis B, Goa KL . Telmisartan: a review of its use in hypertension. Drugs 2001; 61: 1501–1529.

    Article  CAS  Google Scholar 

  63. Manolis AJ et al. Angiotensin II receptor antagonist telmisartan in isolated systolic hypertension (ARAMIS) study: efficacy and safety of telmisartan 20, 40 or 80 mg versus hydrochlorothiazide 12.5 mg or placebo. J Hypertens 2004; 22: 1033–1037.

    Article  CAS  Google Scholar 

  64. Croom KF, Curran MP, Goa KL, Perry CM . Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy. Drugs 2004; 64: 999–1028.

    Article  CAS  Google Scholar 

  65. Lacourciere Y . A multicenter, randomized, double-blind study of the antihypertensive efficacy and tolerability of irbesartan in patients aged> or =65 years with mild to moderate hypertension. Clin Ther 2000; 22: 1213–1224.

    Article  CAS  Google Scholar 

  66. Gardner SF, Franks AM . Olmesartan medoxomil: the seventh angiotensin receptor antagonist. Ann Pharmacother 2003; 37: 99–105.

    Article  CAS  Google Scholar 

  67. Brousil JA, Burke JM . Olmesartan medoxomil: an angiotensin II-receptor blocker. Clin Ther 2003; 25: 1041–1055.

    Article  CAS  Google Scholar 

  68. Chrysant SG, Marbury TC, Robinson TD . Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension. J Hum Hypertens 2003; 17: 425–432.

    Article  CAS  Google Scholar 

  69. Warner GT, Jarvis B . Olmesartan medoxomil. Drugs 2002; 62: 1345–1353.

    Article  CAS  Google Scholar 

  70. Hansson L et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755–1762.

    Article  CAS  Google Scholar 

  71. Douglas JG et al. Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med 2003; 163: 525–541.

    Article  Google Scholar 

  72. Benedict CR . Safe and effective management of hypertension with fixed-dose combination therapy: focus on losartan plus hydrochlorothiazide. Int J Clin Pract 2000; 54: 48–54.

    CAS  PubMed  Google Scholar 

  73. Lacourciere Y, Poirier L . Antihypertensive effects of two fixed-dose combinations of losartan and hydrochlorothiazide versus hydrochlorothiazide monotherapy in subjects with ambulatory systolic hypertension. Am J Hypertens 2003; 16: 1036–1042.

    Article  CAS  Google Scholar 

  74. Conlin PR et al. Angiotensin II antagonists for hypertension: are there differences in efficacy? Am J Hypertens 2000; 13: 418–426.

    Article  CAS  Google Scholar 

  75. Dahlof B et al. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group. Am J Hypertens 1997; 10: 705–713.

    Article  CAS  Google Scholar 

  76. Kjeldsen SE et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA 2002; 288: 1491–1498.

    Article  CAS  Google Scholar 

  77. Alderman M, Aiyer KJV . Uric acid—role in cardiovascular disease and effects of losartan. Curr Med Res Opin 2004; 20: 369–379.

    Article  CAS  Google Scholar 

  78. Dahlof B et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995–1003.

    Article  CAS  Google Scholar 

  79. Schupp M et al. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004; 109: 2054–2057.

    Article  CAS  Google Scholar 

  80. Julius S et al. VALUE trial: long-term blood pressure trends in 13 449 patients with hypertension and high cardiovascular risk. Am J Hypertens 2003; 16: 544–548.

    Article  Google Scholar 

  81. Julius S et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 2004, 1–10.

  82. Weber M . The telmisartan Programme of Research tO show Telmisartan End-organ proteCTION (PROTECTION) programme. J Hypertens 2003; 21 (Suppl 6): S37–S46.

    Article  CAS  Google Scholar 

  83. Nelson EC, Stason WB, Neutra RR, Solomon HS . Identification of the noncompliant hypertensive patient. Prev Med 1980; 9: 504–517.

    Article  CAS  Google Scholar 

  84. Croog SH et al. The effects of antihypertensive therapy on the quality of life. N Engl J Med 1986; 314: 1657–1664.

    Article  CAS  Google Scholar 

  85. Okereke CE, Messerli FH . Efficacy and safety of angiotensin II receptor blockers in elderly patients with mild to moderate hypertension. Am J Geriatr Cardiol 2001; 10: 42–49.

    Article  CAS  Google Scholar 

  86. Mazzolai L, Burnier M . Comparative safety and tolerability of angiotensin II receptor antagonists. Drug Saf 1999; 21: 23–33.

    Article  CAS  Google Scholar 

  87. Pylypchuk GB . ACE inhibitor- versus angiotensin II blocker-induced cough and angioedema. Ann Pharmacother 1998; 32: 1060–1066.

    Article  CAS  Google Scholar 

  88. Goldberg AI, Dunlay MC, Sweet CS . Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol 1995; 75: 793–795.

    Article  CAS  Google Scholar 

  89. Oparil S et al. Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension. Clin Ther 1996; 18: 608–625.

    Article  CAS  Google Scholar 

  90. Weir MR et al. Efficacy, tolerability, and quality of life of losartan, alone or with hydrochlorothiazide, versus nifedipine GITS in patients with essential hypertension. Clin Ther 1996; 18: 411–428.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Writing assistance for this paper was provided by Kala JV Aiyer, PhD, and funding was provided by Merck & Co., Inc., Whitehouse Station, NJ 08889, USA.

Author information

Authors and Affiliations

  1. Cattedra di Cardiologia, II Facoltà di Medicina e Chirurgia, Università di Roma ‘La Sapienza’, Rome, Italy

    M Volpe

  2. IRCCS Neuromed, Pozzilli, IS, Italy

    M Volpe

Authors
  1. M Volpe
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Volpe, M. Treatment of systolic hypertension: spotlight on recent studies with angiotensin II antagonists. J Hum Hypertens 19, 93–102 (2005). https://doi.org/10.1038/sj.jhh.1001781

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.jhh.1001781

Keywords

This article is cited by

Search

Advanced search

Quick links